Patients that will most probably benefit from NACT include high tumor-to-breast volume ratio; ref. [1] lymph-node-positive [2] and specific biological features of primary cancer as high-grade disease; [3] hormone receptor negative breast cancer (BC); triple negative (TN) [4] and overexpression of human epidermal growth factor receptor 2 (HER2+) phenotypes, even at an early stage (EBC). This evidence concerns the gene ERBB2 and neoplasm.